<DOC>
	<DOCNO>NCT02714634</DOCNO>
	<brief_summary>Approximately , 40 50 % patient rheumatoid arthritis ( RA ) , frequent inflammatory arthritide , non responder consensual 1st line treatment : methotrexate . In patient , well demonstrated addition immunomodulatory drug ( ) often result significant improvement . However , best option regard drug ( ) add remain unclear . Rheumatologists currently use add targeted biologic therapy , anti-TNFα , recently abatacept tocilizumab . Triple therapy use 3 conventional disease-modifying drug ( DMARDs ) , methotrexate+salazopyrine+hydroxychloroquine could alternative option biologics , favorable safety profile much low cost . Uncertainty remain regard superiority biologics triple therapy methotrexate insufficient responder ( IR ) . Investigators decide address issue perform randomize control pragmatic trial .</brief_summary>
	<brief_title>Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate , Salazopyrine Hydroxychloroquine Patients With Rheumatoid Arthritis Insufficient Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>Patient rheumatoid arthritis accord EULAR/ACR 2010 criterion DAS28CRP &gt; 3.2 Insufficient response methotrexate weekly dose≥15mg least 3 month RA radiographic erosion and/or serum rheumatoid factor associate antiCyclic Citrullinated Peptide ( AntiCCP ) Age great equal 18 year Written inform consent , date sign initiate trialrelated procedure Affiliation social insurance system Women child bear potential , negative βHCG assay ( Human chorionic gonadotropin ) Effective method birth control study continue 5 month end study men depend biotherapy associate woman ( referred summary product characteristic ) . Previous treatment one evaluate biologics Previous treatment triple therapy Other inflammatory arthritis except RA associate Sjögren 's syndrome Contraindication biologics methotrexate , sulfasalazine hydroxychloroquine Corticosteroids dose &gt; 15 mg/d equivalent prednisone least 4 week inclusion Absence tuberculosis screen Patient follow 12 month Pregnancy , breastfeeding , desire pregnancy 12 month Drug addiction , addiction alcohol Participation clinical study investigational product within 4 week prior start study treatment Women child bear potential , unless use effective method birth control Patient law protection Prisoners</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>